# Mixture and Non-Mixture Cure Models for the survival analysis of SARS-CoV-2 patients in Khyber Pakhtunkhwa, Pakistan

## TL;DR

This study analyzed survival differences between asymptomatic and symptomatic SARS-CoV-2 patients in Pakistan, finding that symptomatic patients had higher death risk but longer survival times.

## Contribution

The paper introduces cure-survival models to analyze SARS-CoV-2 patient outcomes, contrasting with traditional Cox models.

## Key findings

- Symptomatic patients had a higher risk of death but longer survival times compared to asymptomatic patients.
- Age influenced the probability of death but not short-term survival time.
- Gender had no significant effect on survival outcomes.

## Abstract

To examine the potential difference in survival and risk of death between asymptomatic and symptomatic SARS-CoV-2 patients, controlled by age and gender for all the attendance in hospitals of Khyber Pakhtunkhwa (KP), Pakistan.

In this retrospective study, the medical records of 6273 SARS-CoV-2 patients admitted to almost all hospitals in Khyber Pakhtunkhwa during the first wave of the coronavirus outbreak from March to June 2020 were analysed. The effects of gender, age, and being symptomatic on the survival of SARS-CoV-2 patients were assessed using cure-survival models as opposed to the conventional Cox proportional hazards model.

The prevalence of initially symptomatic patients was 55.8%, and the overall mortality rate was 11.8%. The fitted cure-survival models suggest that age affects the probability of death (incidence) but not the short-term survival time of patients (latency); symptomatic patients have a higher risk of death than their asymptomatic counterparts, but the survival time of symptomatic patients is longer on average; gender has no significant effect on the probability of death and survival time.

The available data and statistical results suggest that asymptomatic and young patients are generally less susceptible to initial infection with SARS-CoV-2 and therefore have a lower risk of death. Our regression models show that uncured asymptomatic patients generally have poorer short-term survival than their uncured symptomatic counterparts. The association between gender and survival outcome was not significant.